Avacta has today published new data which demonstrates the more favorable delivery and advantages of the proprietary pre|CISION platform, compared to a marketed antibody drug conjugate (ADC).
The data analysis compares pre|CISION FAP-cleavable payload delivery with that of Enhertu®, a protease cleavable-linker ADC, approved for both breast cancer and gastric cancer indications (an AstraZeneca/Daiichi Sankyo product, trastuzumab-deruxtecan [T-Dxd], an exatecan-derivative ADC).
“This data analysis validates that our pre|CISION payload delivering mechanism has many potential key advantages over the ADC mechanism, currently one of the most successful drug classes in oncology. We are excited to initiate the Phase 1 clinical trial of AVA6103) program shortly, in Q1 2026,” said Christina Coughlin, CEO of Avacta.